Ultragenyx’s Rare‑Disease Stock Soars After FDA Greenlights First Sanfilippo Gene Therapy

The biotech world got a jolt on Thursday when the U.S. Food and Drug Administration finally signed off on Fayuvi – also known by its code name UX111 – marking the first ever gene‑therapy for Sanfilippo syndrome type A. For Ultragenyx Pharmaceutical (ticker RARE), the news translated into a brisk 13 % surge during the day, followed by a modest 3 % lift in after‑hours trading.

Sanfilippo syndrome, sometimes dubbed “childhood Alzheimer’s,” is a devastating rare disorder caused by a missing enzyme that lets a sugar molecule, heparan sulfate, pile up in the brain. The result? A heartbreaking loss of speech, cognition and motor skills in young children. Fayuvi works by delivering a single dose of a harmless, modified virus that carries a functional copy of the missing gene. Once inside the cells, the gene prompts the body to produce the enzyme and, hopefully, clear the toxic buildup.

Clinical data that the FDA reviewed showed treated children between ages 2 and 5 either maintained or improved their cognitive scores, whereas historical, untreated patients typically plateaued and then declined. In fact, Ultragenyx reported a 23.5‑point advantage on a standard cognitive metric compared with natural‑history controls. The most common side‑effects were modest – elevated liver enzymes, occasional vomiting and low‑grade fevers.

It’s worth noting that this isn’t the first time the FDA looked at Fayuvi. Back in 2025 the agency rejected the therapy, not because of safety or efficacy concerns, but due to manufacturing hiccups. Ultragenyx went back to the drawing board, fixed the production issues, and resubmitted the dossier. The clock was set for a decision by September 19, and the approval landed a day earlier than expected.

From a pricing perspective, the company has set the U.S. wholesale acquisition cost at a staggering $3.95 million per patient. While that figure will spark debates about accessibility, it also underscores the high‑stakes nature of cutting‑edge gene therapies.

Market reaction was, unsurprisingly, enthusiastic. After flirting with a 52‑week low of $12.73 just a day before, the stock rallied strongly, still trading well below the highs it enjoyed in early September when a late‑stage Angelman‑syndrome trial caused a 44 % plunge in a single session. Retail chatter on platforms like Stocktwits shifted from “bullish” to “extremely bullish” within 24 hours, with message volume spiking to “extremely high.” One trader even mused that the priority‑review voucher accompanying the approval, valued at roughly $200 million, could act as a catalyst for further upside.

Some optimistic voices are already penciling in a target price of $25 per share, betting that the premium pricing and the rarity of the therapy will keep investors interested. Yet, it’s hard to ignore the broader context: RARE is down about 37 % year‑to‑date, and the biotech sector remains sensitive to regulatory twists.

Looking ahead, the therapy is expected to roll out to qualified U.S. treatment centers within the next 30 to 60 days. If the early clinical signals hold up in the real‑world setting, Ultragenyx could not only improve the lives of a handful of children but also solidify its position as a leader in the rare‑disease gene‑therapy arena.

For investors and observers alike, Thursday’s approval serves as a reminder that persistence – even after a regulatory setback – can eventually pay off, sometimes in the form of a multi‑million‑dollar price tag and a noticeable stock bounce.